Business Wire

Serbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity Science

21.9.2026 14:02:00 EEST | Business Wire | Press release

Share

BioEridan, a Serbian biotechnology startup backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a new documentary showcasing its development of underwater Aquafarms and its ambition to contribute to the next generation of longevity science.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921345879/en/

BioEridan Documentary Premiere

BioEridan: Science Beneath the Surface premiered in Belgrade on September 15 before being screened the following day at a UK-Serbia Health, Digital Transformation & Innovation roundtable held at Christ’s College, University of Cambridge, as part of Cambridge Tech Week 2026.

The roundtable brought together prominent representatives from the UK and Serbia across science, healthcare, technology, academia and business to discuss opportunities for collaboration, innovation and the commercialisation of scientific research.

The documentary follows BioEridan’s development from an early scientific project in Serbia to the creation of underwater Aquafarms designed to support biotechnology research. Located approximately 13 metres beneath the sea, the Aquafarms use controlled hydroponic systems to cultivate plants in a highly controlled environment for biotechnology research.

At the heart of BioEridan’s mission is the pursuit of new approaches to longevity and healthy ageing, including research related to telomeres — protective structures at the ends of chromosomes that play an important role in cellular ageing. BioEridan is working on the production of a bioactive ingredient that it aims to develop for use in future longevity-focused products.

Dr Jelena Milovanović, Founder and CEO of BioEridan, said: “BioEridan was founded on the belief that transformative science can come from anywhere. This documentary tells the story of our journey and explores whether some of the next breakthroughs in longevity science may already exist in nature, waiting to be discovered. From Serbia, we want to build a new model for biotechnology that is ambitious in its science, responsible in its use of nature and capable of improving lives around the world.”

The screening at Christ’s College formed part of BioEridan’s participation in the UK-Serbia Health, Digital Transformation & Innovation Forum on September 16. The event provided an opportunity to present BioEridan’s research and technology to an international audience and to explore potential partnerships connecting Serbian scientific and entrepreneurial talent with the UK’s world-leading research and innovation ecosystem.

BioEridan is supported by TS Ventures Fund, the first corporate venture capital fund established in this part of Europe. Founded in 2021, the €25 million fund invests in technology and business solutions across Serbia and international markets, with areas of focus including life sciences, artificial intelligence, cybersecurity, fintech and software.

Davor Sakač, CEO of TS Ventures Fund, said: “BioEridan demonstrates the depth of scientific talent and entrepreneurial ambition emerging from Serbia. Its journey from Belgrade to Cambridge shows how a promising scientific idea can develop into a venture with international ambitions. The launch of this documentary and BioEridan’s participation in Cambridge Tech Week bring its story and technology to a wider global audience, while reflecting TS Ventures Fund’s role in helping promising companies develop, scale and build connections with leading innovation ecosystems.”

The documentary’s launch marks another milestone in BioEridan’s development as it expands its research capacity and international profile, with the ambition of establishing Serbia as a recognised contributor to biotechnology and longevity science.

About BioEridan

BioEridan is a Serbian biotechnology company focused on longevity research and the discovery and development of innovative bioactive compounds. The company combines biotechnology, marine science and controlled underwater cultivation through its proprietary Aquafarm platform, with the aim of developing new solutions for healthy ageing and supporting the next generation of longevity science.

About Telekom Srbija Group

Telekom Srbija Group is one of the leading telecommunications and technology companies in Southeast Europe, serving more than 14 million customers across 15 markets regionally and globally. The Group provides a comprehensive portfolio of connectivity, digital and multimedia services, while accelerating its transformation into the Telco of the Future through investments in next-generation infrastructure, 5G, artificial intelligence, cybersecurity, digital services and premium content. Through strategic partnerships and its innovation ecosystem, including TS Ventures Fund, Telekom Srbija Group is supporting the growth of new technologies and contributing to the digital transformation of the region and beyond.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260921345879/en/

Contacts

Ivana Bajović
ivanabajo@telekom.rs
+381 64 650 7300

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 14:24:00 EEST | Press release

Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking expertise with Solos' proprietary dealcoholization and patented aroma recovery technology. With 30 years of experience in producing alcohol-free sparkling wines, Henkell Fre

Croma-Pharma Expands Its Portfolio in Canada With saypha ® lips Lidocaine and Exprecell™5.10.2026 14:12:00 EEST | Press release

Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia

Anaeco Secures Strategic Investment from Momentum Global Ventures to Accelerate Commercial Deployment5.10.2026 13:00:00 EEST | Press release

Anaeco, Inc., a clean technology company developing systems to destroy harmful and difficult-to-abate gases, today announced a strategic investment from Momentum Global Ventures. The investment supports Anaeco as it moves from technology development and validation to commercial deployment across three initial markets: anesthetic gases, refrigerants, and semiconductor manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005546122/en/ Anaeco’s technology exploits atmospheric chemistry to destroy harmful, high-impact gases, including HFCs, PFAS, anesthetic gases, N2O, and other difficult-to-abate emissions at their source. By accelerating processes that naturally transform pollutants, its modular technology provides a practical, scalable approach to emissions that are difficult or costly to manage conventionally. Initial Commercial Verticals Anesthetics: Destroying anesthetic gases generated in healthcare environmen

Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform with the Addition of MOSS EOS for Early Onset Scoliosis Surgery5.10.2026 12:00:00 EEST | Press release

Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the selective market introduction of the MOSS EOS® System for the treatment of children with severe early onset scoliosis.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005092768/en/ Early Onset Scoliosis is a rare pediatric disease where in certain cases surgical intervention can be indicated.2 Breaking new ground, Biedermann Motech will now introduce the world’s first MOSS EOS System featuring MOSS!MODULARITY™ to selective markets outside the U.S. The MOSS EOS System encompasses a modular platform of products and technologies for growth friendly pediatric spinal deformity surgery. Prof. Dr. Heiko Koller from Germany, one of the innovators behind the MOSS EOS System, carried out the first surgeries. His feedback was that the versatility of the system offers surgeons a broad range

LTM Launches BlueVerse™ AgenTraceIQ5.10.2026 11:30:00 EEST | Press release

LTM, the Business Creativity partner to the world's largest enterprises, today announced the launch of BlueVerse™ AgenTraceIQ, an offering designed to help organizations securely adopt and scale agentic AI. Combining Rubrik Agent Cloud with LTM's AI governance and managed services expertise, the offering enables organizations to monitor AI agents, establish guardrails, and rewind unintended agent actions across business-critical environments. Aspart of Rubrik’s Project Hourglass, LTM and other elite Global Systems Integrators partner with Rubrik, the Security and AI Operations Company, to deliver Rubrik Agent Cloud for Anthropic's Claude Code to their enterprise clients. The collaboration strengthens the ability for organizations to adopt agentic systems with the necessary security, governance, and resilience at scale. "As AI agents increasingly act autonomously, the stakes for enterprise security and resilience have never been higher. Together with LTM, we are empowering organizations

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye